Zoetis Inc.

ZTS

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001555280

A/B

on the A/B boundary of 367 graded peers in healthcare

rank 75 of 367; percentile 20.2; sampling error 2.5 points; lower is stronger


A B C D E

A/B, the bull




Scoreboard	
Profitability	B/C percentile 38.0
Solvency	B/C percentile 37.9
Growth and financing	B/C percentile 38.7
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $15.5B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Feb 12, 2026 275 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$83.82 2026-11-13; market equity $34.1B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

In order to sell our products, we must be able to produce and ship our products in sufficient quantities. Many of our products involve complex manufacturing processes and are sole-sourced from certain manufacturing sites. Minor deviations in our manufacturing or logistical processes, such as temperature excursions or improper package sealing, could result in delays, inventory shortages, unanticipated costs, product recalls, product liability and/or regulatory action. In addition, a number of factors could cause production interruptions that could result in launch delays, inventory shortages, recalls, unanticipated costs or issues with our supply agreements with third parties.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 38.0						
Gross profitability	44.0%	32.3%		28.0	365	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(1.6%)	(6.6%)	77.8	799	2025-12-31
Gross margin stability, five years	0.7 pts	2.8 pts	8.3	242	2025-12-31
Solvency, sleeve percentile 37.9					
Twelve-month failure probability	0.04%	0.08%	20.5	245	2026-09-30
Altman Z double-prime	not computable	(0.31)			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	3.03x	2.96x	55.2	825	2025-12-31
Growth and financing, sleeve percentile 38.7					
Revenue growth, three-year compound	5.4%	10.1%	58.5	411	2025-12-31
Free cash flow growth, three-year compound	19.9%	11.0%	44.7	95	2025-12-31
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	1.2%	2.3%	49.1	693	2025-12-31
Net share issuance, one year	(5.7%)	2.4%	2.6	627	2026-02-06

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
70	Dexcom Inc. (DXCM)	18.9	A/B	fortress balance sheet
71	Adma Biologics, Inc. (ADMA)	19.1	A/B	late filer, fortress balance sheet
72	Orthofix Medical Inc. (OFIX)	19.4	A/B	
73	Merit Medical Systems Inc. (MMSI)	19.7	A/B	
74	Boston Scientific Corp. (BSX)	19.9	A/B	
75	Zoetis Inc. (ZTS)	20.2	A/B	
76	Ocular Therapeutix, Inc. (OCUL)	20.5	A/B	dilution
77	Alpha PRO Tech Ltd. (APT)	20.8	A/B	
78	Lineage Cell Therapeutics, Inc. (LCTX)	21.0	A/B	
79	Siga Technologies Inc. (SIGA)	21.3	A/B	fortress balance sheet
80	West Pharmaceutical Services Inc. (WST)	21.6	A/B	fortress balance sheet

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(50.8%)	(1.5%)	14
Distance from 52-week high	(36.1%)	(32.0%)	43
EBIT to enterprise value	not computable	(1.8%)	
Free cash flow yield	6.7%	(1.0%)	87

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.10	0.29	24
Sales to price	0.28	0.29	48
Composite equity issuance, five years	(21.5%)	19.1%	8
Relative strength against the sector, log excess return	(0.88)	(0.18)	14

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 8 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.3B
Operating cash flow, four quarters	$2.7B
Months of runway	not finite
Days since last periodic filing	9 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$309.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$9.5B	2025-12-31	2026-02-12	10-K	26-000011
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.7B	2025-12-31	2026-02-12	10-K	26-000011
3	assets	us-gaap:Assets	$15.5B	2025-12-31	2026-02-12	10-K	26-000011
4	net income	us-gaap:NetIncomeLoss	$2.7B	2025-12-31	2026-02-12	10-K	26-000011
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.9B	2025-12-31	2026-02-12	10-K	26-000011
6	assets	us-gaap:Assets	$14.2B	2024-12-31	2026-02-12	10-K	26-000011
7	revenue	us-gaap:Revenues	$9.3B	2024-12-31	2026-02-12	10-K	26-000011
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.7B	2024-12-31	2026-02-12	10-K	26-000011
9	revenue	us-gaap:Revenues	$8.5B	2023-12-31	2026-02-12	10-K	26-000011
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.6B	2023-12-31	2026-02-12	10-K	26-000011
11	revenue	us-gaap:Revenues	$8.1B	2022-12-31	2025-02-13	10-K	25-000102
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.5B	2022-12-31	2025-02-13	10-K	25-000102
13	revenue	us-gaap:Revenues	$7.8B	2021-12-31	2024-02-13	10-K	24-000143
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.3B	2021-12-31	2024-02-13	10-K	24-000143
15	current assets	us-gaap:AssetsCurrent	$6.8B	2025-12-31	2026-02-12	10-K	26-000011
16	current liabilities	us-gaap:LiabilitiesCurrent	$2.2B	2025-12-31	2026-02-12	10-K	26-000011
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$621.0M	2025-12-31	2026-02-12	10-K	26-000011
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.0B	2024-12-31	2026-02-12	10-K	26-000011
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$655.0M	2024-12-31	2026-02-12	10-K	26-000011
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.4B	2023-12-31	2026-02-12	10-K	26-000011
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$732.0M	2023-12-31	2026-02-12	10-K	26-000011
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.9B	2022-12-31	2025-02-13	10-K	25-000102
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$586.0M	2022-12-31	2025-02-13	10-K	25-000102
24	assets	us-gaap:Assets	$14.3B	2023-12-31	2025-02-13	10-K	25-000102
25	assets	us-gaap:Assets	$14.9B	2022-12-31	2024-02-13	10-K	24-000143
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	422,127,709	2026-02-06	2026-02-12	10-K	26-000011

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	shares outstanding	dei:EntityCommonStockSharesOutstanding	447,791,917	2025-02-07	2025-02-13	10-K	25-000102	